| 2024/05/24 | 15:34:23 | Major Subsidiary Medeologix Announces Lifting of Non-Compete Restrictions on Directors at 2024 Annual Shareholders’ Meeting. | |
| SEQ_NO |
5 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:34:23 |
| Subject |
Major Subsidiary Medeologix Announces Lifting of Non-Compete Restrictions on Directors at 2024 Annual Shareholders' Meeting. |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 21 |
| Statement |
1.Date of the shareholders’ meeting resolution:2024/05/24
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Medeon Biodesign, Inc.
Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
Legal Representative of Medeon Biodesign, Inc. Yih-Cheng Shih; Director
Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
ANANT VISHWESHWAR HEGDE; Director
3.Items of competitive conduct in which the officer is
permitted to engage:
Invest in or manage other companies with the same or similar scope of
business as Medeologix
4.Period of permission to engage in the competitive conduct:
During the period of serving as director of Medeologix
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
The proposal was resolved as proposed after the chairman inquired of all
attending shareholders.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter ‘N/A’ below):N/A
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company’s finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None |
|
| 2024/05/24 | 15:26:46 | Announcement of the Election Results for Directors and Supervisor of Major Subsidiary Medeologix at the 2024 Annual Shareholders’ Meeting. | |
| SEQ_NO |
4 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:26:46 |
| Subject |
Announcement of the Election Results for Directors and Supervisor of Major Subsidiary Medeologix at the 2024 Annual Shareholders' Meeting. |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of occurrence of the change:2024/05/24
2.Elected or changed position (Please enter institutional
director, institutional supervisor, independent director,
natural-person director or natural-person supervisor):
institutional director, natural-person director, natural-person supervisor
3.Title and name of the previous position holder:
(1) Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
(2) Legal Representative of Medeon Biodesign, Inc. Yih-Cheng Shih; Director
(3) Legal Representative of Medeon Biodesign, Inc. Ming Hsiung Wu; Director
(4) Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
(5) ANANT VISHWESHWAR HEGDE; Director
(6) Supervisor: Randy Lin
4.Resume of the previous position holder:
(1) Yue Teh Jang; Chairman of Medeologix Corporation
(2) Yih-Cheng Shih; Director of Medeologix Corporation
(3) Ming Hsiung Wu; Director of Medeologix Corporation
(4) Jenny Chen; Director of Medeologix Corporation
(5) ANANT VISHWESHWAR HEGDE; Director of Medeologix Corporation
(6) Supervisor: Randy Lin; Supervisor of Medeologix Corporation
5.Title and name of the new position holder:
(1) Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
(2) Legal Representative of Medeon Biodesign, Inc. Yih-Cheng Shih; Director
(3) Legal Representative of Medeon Biodesign, Inc. Ming Hsiung Wu; Director
(4) Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
(5) ANANT VISHWESHWAR HEGDE; Director
(6) Supervisor: Randy Lin
6.Resume of the new position holder:
(1) Yue Teh Jang; Chairman of Medeologix Corporation
(2) Yih-Cheng Shih; Director of Medeologix Corporation
(3) Ming Hsiung Wu; Director of Medeologix Corporation
(4) Jenny Chen; Director of Medeologix Corporation
(5) ANANT VISHWESHWAR HEGDE; Director of Medeologix Corporation
(6) Supervisor: Randy Lin; Supervisor of Medeologix Corporation
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’, ‘death’ or ‘new appointment’):term expired
8.Reason for the change:Term expired re-elected
9.Number of shares held by the new position holder when elected:
(1) Legal Representative of Medeon Biodesign, Inc.
Yue Teh Jang; 52,814,174 shares
(2) Legal Representative of Medeon Biodesign, Inc.
Yih-Cheng Shih; 52,814,174 shares
(3) Legal Representative of Medeon Biodesign, Inc.
Ming Hsiung Wu; 52,814,174 shares
(4) Legal Representative of Medeon Biodesign, Inc.
Jenny Chen; 52,814,174 shares
(5) ANANT VISHWESHWAR HEGDE; 1,785,826 shares
(6) Supervisor: Randy Lin; 0 shares
10.Original term (from __________ to __________):2021/12/24~2024/12/23
11.Effective date of the new appointment:2024/05/24
12.Turnover rate of directors of the same term:NA
13.Turnover rate of independent directors of the same term:NA
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter ‘Yes’ or
‘No’):No
16.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2024/05/24 | 15:10:18 | Announcement for the important resolutions at the 2024 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix | |
| SEQ_NO |
2 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:10:18 |
| Subject |
Announcement for the important resolutions at the 2024 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2024/05/24
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2023 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:
Approval of the amendment to the Articles of Incorporation.
4.Important resolutions III.Business report and financial statements:
Ratification of 2023 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:
Election the 3rd session of Directors and Supervisor
6.Important resolutions V.Other matters:
Approval for the release of newly elected directors or its representatives
from Non-Competition Restrictions.
7.Any other matters that need to be specified:None |
|
| 2024/05/24 | 15:04:16 | Announcement for the important resolutions at the 2024 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, Prodeon Medical Corporation | |
| SEQ_NO |
1 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:04:16 |
| Subject |
Announcement for the important resolutions at the 2024 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, Prodeon Medical Corporation |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2024/05/24
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2023 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Ratification of 2023 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:None
7.Any other matters that need to be specified:None |
|
| 2024/05/02 | 17:06:28 | Medeon Board of Directors resolved not to proceed the private placement of common shares approved by the 2023 Annual Shareholders’ Meeting. | |
| SEQ_NO |
2 |
Date of announcement |
2024/05/02 |
Time of announcement |
17:06:28 |
| Subject |
Medeon Board of Directors resolved not to proceed the private placement of common shares approved by the 2023 Annual Shareholders' Meeting. |
| Date of events |
2024/05/02
|
To which item it meets |
paragraph 16 |
| Statement |
1.Date of the board of directors resolution for the change:2024/05/02
2.Effective registration date of the original plan:NA
3.Resolution date of additional issuance:NA
4.Major change Reason for the change:
The Company resolved on June 19, 2023 to proceed with the issuing no
more than 35,000,000 common shares for capital increase through private
placement by the Shareholders’Meeting. The issuing shall be completed
within 1 year from the date of the resolution of the Shareholders’
Meeting, with the maximum number of installments not exceeding three.
Due to the period of the private placement proposal is going to expire
and the qualified strategic investors have not yet been identified, the
Medeon board meeting dated May 2, 2024 has resolved not to proceed the
private placement of common shares for rest of the period.
5.Content of each and every successive previously changed
plan for raising of funds before and after change:NA
6.Projected timetable for execution:NA
7.Projected completion date:NA
8.Projected possible benefits:NA
9.Difference from original projected benefits:NA
10.Effect of the current change on shareholder equity:NA
11.Abstract of the original lead underwriter’s appraisal opinion:NA
12.Any other matters that need to be specified:None |
|
| 2024/05/02 | 17:00:38 | Medeon Board of Directors approved the 2024Q1 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2024/05/02 |
Time of announcement |
17:00:38 |
| Subject |
Medeon Board of Directors approved the 2024Q1 consolidated financial reports |
| Date of events |
2024/05/02
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2024/05/02
2.Date of the audit committee approved:2024/05/02
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/03/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):47,141
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):4,154
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(227,124)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(214,799)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(214,513)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(199,827)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(2.17)
11.Total assets end of the period (thousand NTD):2,557,756
12.Total liabilities end of the period
(thousand NTD):379,695
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,133,549
14.Any other matters that need to be specified:None |
|
| 2024/04/24 | 16:33:45 | Announcement for the Board of Directors meeting date to approve the first-quarter 2024 financial report | |
| SEQ_NO |
1 |
Date of announcement |
2024/04/24 |
Time of announcement |
16:33:45 |
| Subject |
Announcement for the Board of Directors meeting date to approve the first-quarter 2024 financial report |
| Date of events |
2024/04/24
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of a notice of the board of directors meeting is issued:2024/04/24
2.Expected date of the board of directors meeting is convened:2024/05/02
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:First-Quarter 2024
4.Any other matters that need to be specified:None |
|
| 2024/02/29 | 17:06:57 | BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved to convene the 2024 Annual Shareholders’ meeting | |
| SEQ_NO |
6 |
Date of announcement |
2024/02/29 |
Time of announcement |
17:06:57 |
| Subject |
BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved to convene the 2024 Annual Shareholders’ meeting |
| Date of events |
2024/02/29
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors resolution:2024/02/29
2.General shareholders’ meeting date:2024/05/24
3.General shareholders’ meeting location:
No. 116, Hougang St., Shilin Dist., Taipei City, Taiwan (R.O.C.)
4.Cause for convening the meeting I.Reported matters:
(1) 2023 Business Report
(2) 2023 Supervisor’s Review Report
5.Cause for convening the meeting II.Acknowledged matters:
(1) 2023 Business Report and Financial Statements
(2) 2023 deficit offset proposal
6.Cause for convening the meeting III, Matters for Discussion:NA
7.Cause for convening the meeting IV.Election matters:NA
8.Cause for convening the meeting V.Other Proposals:NA
9.Cause for convening the meeting VI.Extemporary Motions:NA
10.Book closure starting date:2024/04/25
11.Book closure ending date:2024/05/24
12.Any other matters that need to be specified:NA |
|
| 2024/02/29 | 17:01:20 | BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved not to distribute dividends | |
| SEQ_NO |
5 |
Date of announcement |
2024/02/29 |
Time of announcement |
17:01:20 |
| Subject |
BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved not to distribute dividends |
| Date of events |
2024/02/29
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2024/02/29
2.Type and monetary amount of dividend distribution:not to distribute
3.Any other matters that need to be specified:None |
|
| 2024/02/29 | 16:59:40 | Medeon Board of Directors resolved the convening of the 2024 Annual Shareholders’ Meeting | |
| SEQ_NO |
4 |
Date of announcement |
2024/02/29 |
Time of announcement |
16:59:40 |
| Subject |
Medeon Board of Directors resolved the convening of the 2024 Annual Shareholders' Meeting |
| Date of events |
2024/02/29
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors resolution:2024/02/29
2.General shareholders’ meeting date:2024/06/12
3.General shareholders’ meeting location:
11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City, Taiwan (R.O.C.)
(MasterLink Securities Conference Room)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):Physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:
(1) To Report the Company’s 2023 Business Report
(2) To Report Audit Committee’s Review Report on the
2023 Financial Statements
(3) To Report the Implementation Status of the Private Placement
(4) To Report the Directors’ Remuneration for the year 2023
6.Cause for convening the meeting II.Acknowledged matters:
(1) To ratify the Company’s 2023 Business Report
and Financial Statements
(2) To Ratify the Company’s 2023 deficit offset proposal
7.Cause for convening the meeting III.Matters for Discussion:
(1) Proposal of the private placement by issuing common shares
8.Cause for convening the meeting IV.Election matters:
(1) To elect the 6th session of Directors
9.Cause for convening the meeting V.Other Proposals:
(1) To release newly elected directors or its representatives from
Non-Competition Restrictions
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2024/04/14
12.Book closure ending date:2024/06/12
13.Any other matters that need to be specified:None |
|
